Smith & Nephew plc announced two new U.S. distribution agreements that broaden its trauma and extremities portfolio. On February 24, 2026, the company entered into an exclusive partnership with RMR Ortho to bring the A’TOMIC™ Nitinol Fixation System into its Trauma, Foot & Ankle and Hand & Wrist lines. The following day, on February 23, 2026, Smith & Nephew announced a distribution agreement with SI‑BONE for its iFuse TORQ portfolio, which includes the iFuse TORQ TNT and iFuse TORQ implants for percutaneous pelvic fracture fixation and sacroiliac joint fusion.
The A’TOMIC system is a dynamic compression fixation solution that uses nitinol, a shape‑memory alloy, to provide stable, compressive fixation for fractures and arthrodesis procedures. The product has received FDA clearance and is positioned to address key surgeon priorities of implant integrity and patient comfort.
"This partnership with RMR Ortho strengthens Smith+Nebhew's fixation portfolio by adding a dynamic compression fixation solution that complements our existing technologies. The A'TOMIC Nitinol Fixation System expands our ability to participate in high‑frequency fracture and arthrodesis procedures while leveraging our established Extremities and Trauma sales channel to deepen surgeon engagement. This collaboration reflects our disciplined approach to portfolio expansion and our continued focus on driving sustainable growth," said Scott Gunn, Vice President of U.S. Marketing, Trauma, Extremities, and Shoulder.
SI‑BONE’s iFuse TORQ TNT has earned FDA Breakthrough Device designation and is eligible for Medicare New Technology Add‑on Payment (NTAP), potentially adding up to $4,136 per procedure. The partnership gives Smith & Nephew access to SI‑BONE’s well‑established sales channel and expands its product offerings in the U.S. extremities market.
"We're incredibly excited to partner with SI‑BONE. This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI‑BONE's industry leadership with Smith+Nebhew's established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth," added Gunn.
These agreements reinforce Smith & Nephew’s strategy of portfolio expansion through strategic partnerships. By adding two FDA‑cleared, high‑profile products to its U.S. distribution network, the company positions itself to capture a larger share of the trauma and extremities market, potentially generating incremental revenue and strengthening its competitive stance. The moves come after a period of modest revenue growth—Q4 2024 revenue was $1,571 million, and Q3 2025 revenue was $1,501 million—highlighting the importance of new product channels to sustain growth momentum.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.